ood morning, and welcome to the proverbial final Friday of summer. STAT reporter Rebecca Robbins here, filling in to bring your daily serving of headlines from the world of pharma. There’s just a few more hours of meetings, deadlines, and workaday responsibilities before the three-day weekend celebrating all that labor. Do try to relax, and be sure to stay safe, whatever it is you do. And while you’re still plugged in, do drop us a note if you hear anything interesting.

Indivior (LON:INDV) saw its stock price plummet after a U.S. court ruling opened the door to a generic rival to its treatment for opioid addiction, Reuters informs us. The company’s Suboxone film that dissolves under the tongue has an average market share of 60 percent in the U.S., but that could change if the Indian generics maker Dr. Reddy’s (RDY) comes in with a generic competitor.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Waterbury is a financial mess, like Connecticut in general. For once I would like to see a city that’s NOT fighting insolvency sue a drug house. Per David Crosby, will be a long time coming.

  • May I observe that the FDA blog post from the Commissioner is only ‘new news’ to those who don’t attend the conferences that FDA participates in. OGD and now the wider CDER organization have been planning this improvement for at least 18 months that I have been aware of. I guess its time in the sun has finally come.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.